Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2007

01-11-2007 | Thoracic Oncology

Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin

Authors: Dominique Elias, MD, PhD, Diane Goere, MD, Valérie Boige, MD, Niaz Kohneh-Sharhi, MD, David Malka, MD, Gorana Tomasic, MD, Clarisse Dromain, MD, Michel Ducreux, MD, PhD

Published in: Annals of Surgical Oncology | Issue 11/2007

Login to get access

Abstract

Background

Dramatic responses to chemotherapy are occurring more and more frequently in patients with multiple colorectal liver metastases (LMs), leading to resection. In a few patients, some LMs vanish on imaging studies, remain undetected during hepatectomy, and are left in place, which defines the “missing LMs.” The aim of our study was to assess the long-term outcome of such “missing LMs.”

Patients

Between January 1999 and June 2004, among 228 patients treated for colorectal LMs, missing LMs were observed in 16 patients. All the patients were operated within 4 weeks of imaging. Hepatic arterial infusion (HAI) with oxaliplatin was administrated in 12 patients (75%): seven before hepatectomy and five after.

Results

Overall, 69 missing LMs were diagnosed and left in place. Among the persistent LMs resected, a complete pathological response was significantly more often observed in the group with preoperative HAI (6 of 7), than in the group without (2 of 9, P < .02). With a mean follow-up of 51 months (24–90), missing LMs did not reappear in 10 patients (62%). Adjuvant HAI was significantly correlated with the definitive eradication of missing LMs (P < .01), as it was not a complete pathological response. The overall 3-year survival rate of these highly selected 16 patients was 94%.

Conclusion

Colorectal LMs under chemotherapy that vanish on high-quality imaging studies, remain undetected during hepatectomy, and are left in place, are definitively cured in 62% of cases. This excellent result seems to be due to the administration of adjuvant hepatic arterial infusion of chemotherapy and should stimulate new investigations.
Literature
1.
Ducreux M, Ychou M, Laplanche A, Gamelin, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the FNLCC. J Clin Oncol 2005;23:4881–7
2.
Elias D, Lasser P, de Baere B, Doidy L, Billard V, Spencer A, et al. Intermittent exclusion of the liver without vena cava clamping during major hepatectomy. Br J Surg 1995;82:1535–9PubMedCrossRef
3.
Elias D, Roche A, Vavasseur D, Lasser Ph. Induction d’une hypertrophie d’un petit lobe gauche hépatique avant hépatectomie droite élargie, par embolisation portale droite pré-opératoire. Ann Chir 1992;46:404–10PubMed
4.
Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61PubMedCrossRef
5.
Allen PJ, Kemeny N, Jarnagin W, de Matteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–15PubMedCrossRef
6.
Adam R, Avisar A, Giachetti S, Azoulay D, Castaing D, Kustlinger F, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann Surg Oncol 2001;8:347–53PubMedCrossRef
7.
O’Connell MJ, Nagorney DM, Bernath AM, Schoeder G, Fitzgibbons RJ, Mailliard JA, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528–33PubMed
8.
Porta C, Danova M, Accurso S, Tinelli C, Girino M, Ricardi A, et al. Sequential intrahepatic and systemic fluoroperimidine-based chemotherapy for metastatic colorectal cancer confined to the liver: a phase II study. Cancer Chemother Pharmacol 2001; 47:423–8PubMedCrossRef
9.
Maire F, Malka D, Elias D, Boige V, Lièvre A, Louafi S, et al. Hepatic arterial infusion oxaliplatin and intravenous LV5FU2 after resection of colorectal liver metastases. Eur J Cancer 2005; 3, Vol 2: p 190; A670
10.
Elias D, Youssef O, Dideris L, Dromain C, Baton O, Boige V, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86(1):4–9PubMedCrossRef
11.
Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete radiological response of colorectal liver metastasis (LM) after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939–44PubMedCrossRef
12.
Hobday TJ, Cha SS, Sargent DJ, Buroker TR, O’Connell MJ, Goldberg RM, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a NCCTG review. Proc of ASCO 2002; 693:174a
Metadata
Title
Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin
Authors
Dominique Elias, MD, PhD
Diane Goere, MD
Valérie Boige, MD
Niaz Kohneh-Sharhi, MD
David Malka, MD
Gorana Tomasic, MD
Clarisse Dromain, MD
Michel Ducreux, MD, PhD
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9482-9

Other articles of this Issue 11/2007

Annals of Surgical Oncology 11/2007 Go to the issue

Gastrointestinal Oncology

Clinical Implication of CXCL12 Expression in Gastric Cancer

Gastrointestinal Oncology

Short-Term Outcomes After Robotic-Assisted Total Mesorectal Excision for Rectal Cancer

Editorials

Can a Small Nodal Metastasis Reliably Alter Intraoperative Risk/Benefit Decision Making in Breast Cancer Surgery?

Editorials

Stress and Burnout Among Surgical Oncologists: A Call for Personal Wellness and a Supportive Workplace Environment

Gastrointestinal Oncology

A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats

Breast Oncology

Genomic Instability and the Development of Metastatic Lymph Node Tumors